Search
Biogen Inc
BIIBAdd to Watchlist
232.830USD
+3.930+1.72%
Close 10-14 16:00（ET）
34.40BMarket Cap
24.91P/E TTM
Biogen Inc (BIIB) Stock Price Target & Forecast
Analyst Rating
Based on 37 analysts giving stock ratings to Biogen Inc in the past month.
Buy
8 Strong Buy
16 Buy
12 Hold
1 Sell
0 Strong Sell
Target Price
243.264USD+7.78%
BIIB Analyst Recommendation Trends
In the current month, BIIB has received 16 Buy Ratings, 12 Hold Ratings, and 1 Sell Ratings. BIIB average Analyst price target in the last month is 243.264.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
8
8
8
7
7
7
7
7
16
16
17
16
15
12
8
8
12
12
12
14
15
17
21
21
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
37
37
38
38
38
37
37
37
BIIB Analyst Rating for Peer Comparison
Updated: Oct 14, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
9
19
3
1
36
AbbVie Inc
ABBV
8
19
6
0
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
Eli Lilly and Co
LLY
10
18
3
1
0
32
Regeneron Pharmaceuticals Inc
REGN
7
15
9
0
0
31
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Merck & Co Inc
MRK
7
16
8
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Financial Forecasting
Based on analysts' estimates, BIIB EPS is projected to reach 2.050 in FY2026Q3, following reported EPS of 0.660 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
1.61
2.77
2.95
2.05
3.27
Actual
-0.33
2.17
0.66
--
--
Surprise
-120.64%
-21.65%
-77.60%
--
--
FAQs
What is Biogen Inc's expected revenue for the next quarter?
Biogen Inc's expected revenue is 2.64B.
What is Biogen Inc's price target?
Analysts forecast that Biogen Inc's price target is USD 243.26, with the highest forecast at USD 300.00 and the lowest forecast at USD 175.00.
How have Biogen IncBIIB's recent earnings per share performed?
The market expectation was USD 0.66, while Biogen IncBIIB's earnings per share (EPS) for the previous quarter was USD 2.17. EPS for the next quarter is expected at USD 2.05.
What is the analyst rating for Biogen Inc?
Based on the ratings of Biogen Inc's stock from 37 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.